Argus
•
Apr 22, 2026
Moderna, Inc.: Looking for a more favorable entry point
Summary
Moderna Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious and cardiovascular diseases, rare diseases, immunological co
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Roku, Inc.
May 01, 2026
•
ROKU
Analyst Report: AstraZeneca PLC
Apr 30, 2026
•
AZN
The Argus Innovation Model Portfolio
Apr 22, 2026
•
TRGP, BLK, GOOGL, AMAT, AAPL, ANET, SAP, ADI, JPM, DASH, URI, COST, V, WM, LLY, SPGI, UBER, GD, GE, DXCM, PANW, META, NVDA, SYK, SNOW, NYT, ORCL, PWR, SCHW, AMZN
Analyst Report: Block, Inc.
Apr 17, 2026
•
XYZ
Analyst Report: PayPal Holdings, Inc.
Apr 17, 2026
•
PYPL
Analyst Profile
Jasper Hellweg
Associate Analyst: Growth Pharmaceutical, Medical Technology & Financial Technology
At Argus Research, Jasper covers the Growth Pharmaceutical, Medical Technology, and Financial Technology companies. He received his undergraduate degree from Boston University, graduating cum laude with a Bachelor of Science degree in Business Administration with concentrations in Entrepreneurship and Marketing. Prior to joining Argus, Jasper worked in a variety of industries, ranging from investment tradeshow management to musical instrument manufacturing. He started his career at Argus in the Research department and has since widened his scope to also include becoming a regular contributor for the Market Movers and Market Digest publications, the Vickers Weekly Insider Report and Argus' bespoke research on IPOs.
